Search results
Results: 88
Number of items: 88
-
Valk, A. M., Tas, S. W., van Ham, S. M., ten Brinke, A., & T2B! immunity against SARS-CoV-2 study group (2024). Suppressed IgG4 class switching in dupilumab‐ and TNF inhibitor‐treated patients after mRNA vaccination. Allergy, 79(7), 1952–1961. https://doi.org/10.1111/all.16089 -
Kummer, L. Y. L., Fernández Blanco, L., Kreher, C., Bos, A., Kuijper, L. H., Verstegen, N. J. M., van de Sandt, C. E., Konijn, V. A. L., Duurland, M. C., Menage, C., Jorritsma, T., Steenhuis, M., Hagen, R. R., van den Dijssel, J., de Jongh, R., Ashhurst, T., van Gils, M. J., Garcia-Vallejo, J. J., Claireaux, M., ... T2B! immunity against SARS-CoV-2 study group (2024). Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID. RMD OPEN, 10(4), Article e004664. https://doi.org/10.1136/rmdopen-2024-004664 -
van Dam, K. P. J., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Busch, M. H., Verstegen, N. J. M., van Ham, S. M., Tas, S. W., & T2B! immunity against SARS-CoV-2 study group (2023). Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations. Journal of autoimmunity, 135, Article 102984. https://doi.org/10.1016/j.jaut.2022.102984
-
Koers, J., Sciarrillo, R., Derksen, N. I. L., Vletter, E. M., Fillié-Grijpma, Y. E., Raveling-Eelsing, E., Graça, N. A. G., Leijser, T., Pas, H. H., van Nijen-Vos, L. L., Braham, M. V. J., Buisman, A.-M., de Jong, J., Schriek, A. I., Tio-Gillen, A. P., Teng, Y. K. O., Steenhuis, M., Swaneveld, F. H., de Taeye, S. W., ... T2B Consortium (2023). Differences in IgG autoantibody Fab glycosylation across autoimmune diseases. Journal of Allergy and Clinical Immunology, 151(6), 1646-1654. https://doi.org/10.1016/j.jaci.2022.10.035
-
Steuten, J., Bos, A. V., Kuijper, L. H., Claireaux, M., Olijhoek, W., Elias, G., Duurland, M. C., Jorritsma, T., Marsman, C., Paul, A. G. A., Garcia Vallejo, J. J., van Gils, M. J., Wieske, L., Kuijpers, T. W., Eftimov, F., van Ham, S. M., ten Brinke, A., & T2B Consortium (2023). Distinct dynamics of antigen-specific induction and differentiation of different CD11c+Tbet+ B-cell subsets. Journal of Allergy and Clinical Immunology, 152(3), 689-699.e6. https://doi.org/10.1016/j.jaci.2023.02.020 -
van Kempen, Z. L. E., Hogenboom, L., Toorop, A. A., Steenhuis, M., Stalman, E. W., Kummer, L. Y. L., van Dam, K. P. J., Bloem, K., ten Brinke, A., van Ham, S. M., Kuijpers, T. W., Wolbink, G. J., Loeff, F. C., Wieske, L., Eftimov, F., Rispens, T., Strijbis, E. M. M., Killestein, J., & T2B! immunity against SARS-CoV-2 study group (2023). Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis. Annals of Neurology, 93(1), 103-108. https://doi.org/10.1002/ana.26534 -
van Dam, K. P. J., Tas, S. W., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Busch, M. H., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2023). Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity. BMC Infectious Diseases, 23, Article 332. https://doi.org/10.1186/s12879-023-08298-6
Page 3 of 9